ISIS 2922 antisense oligonucleotide directed against an mRNA of cytomegalovirus data

The Carlsbad, Calif., company presented Phase I/II results showing halt of disease progression in two of the three patients given 150 µg and all of five given 300 µg. Two patients given 75 µg had no clinical response to the agent, according to data presented at the meeting of the Federation of American Societies for Experimental Biology.

Progression of the retinitis was measured by photographing the retina, and measuring size and appearance of the lesions. There were no dose-related toxicities, but some adverse events could not clearly be ruled out as drug-induced, such as inflammation, altered vision, and eye pain that resolved. ...